Expert Interview
A Third Opinion: Discussing Tepezza's launch and remaining unmet medical need in treating Thyroid Eye Disease (TED)
Ticker(s): HZNP, VRDN, ValenzaBio, VasaraGenInstitution: Mayo Clinic
- Chair of the Thyroid Core Group for the Division of Endocrinology at Mayo Clinic
- Treats 150 patients with Graves' Disease every year
- Clinical interest in the area of autoimmune thyroid diseases, with a specific interest in Graves' disease and Graves' ophthalmopathy; Research aims to identify novel treatments as well as methods of prevention for these condition, in both retrospective reviews of cases and clinical trials
From member: If you can have the host ask what attributes for a next-generation TED IGFR drug would be ideal, can Tepezza/the space be improved upon? Injectable? Shorter dosing regimen? Room for better efficacy or safety?
Added By: joe_mccannAre you aware of any of the other players?
- Viridian has both an IV and subQ option. Thoughts?
- VasaraGen? Thoughts on an oral IGF-1R + insulin inhibitor option?
Thoughts on IMVT’s batoclimab?
- Showed early positive data but halted due to LDLs. Thoughts on initial efficacy?
- LDL levels concern you?
- Thoughts generally on anti-FcRns in TED?
What are your thoughts on a drug like secukinumab which is approved and well-understood inother indications?
Added By: joe_mccannThis is IV. Thoughts on subQ options?
- HZNP is doing subQ, too. What would a subQ option in TED mean for you? For patients?
Safety
- What are your thoughts on the AE profile based on your experience?
- And safety in your experience v. label?
- Any difference in AE profile in different groups of patients?
- Elderly v. young?
- Chronic v. acute?
Efficacy details:
- Do most patients complete the full 8 infusion tx cycle?
- Have you ever had patients stop early and get full benefit?
- When do you start to see full benefit?
- Anything you wished the drug was better at in term of efficacy?
What are your thoughts on Tepezza?
- Efficacy? In Chronic? Acute?
- Safety? Different in chronic? Acute?
- Do you believe it will be equally effective in chronic patients?
- Thoughts on the Ph4 chronic study expected 2H22?
Do you see chronic (inactive) TED patients or acute (active) or both?
- How do you differentiate between the two?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
